Contemporary pharmacological management of patients after hip fracture: a population-based cohort of over 120,000 patients in Spain
Authors' conclusion
In our study, we found a slight increase in treatment rates over time, but an important treatment gap in the contemporary secondary prevention of hip fracture is still present.
Study context
- Population
- Patients aged ≥65 years discharged alive after hip fracture hospitalisation (Jan 2008–Dec 2021), several regions of Spain (one third of the population)over 120,000 patients
- Outcome
- Proportion of patients prescribed any antiosteoporotic (AO) medication and specific classes
- Follow-up
- First 90 days after discharge
Methodological detailspopulation-based
- Population-based
Main finding
As reported in the abstract
Untreated with AO medication (treatment gap)
Patients untreated
78%
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Treated, by age (subgroup) | Aged ≤ 84 26% · Aged 85 + 18% |
| Treated, by sex (subgroup) | Females 24% · Males 14% |
Share of antiosteoporotic (AO) prescriptions by drug class
- Bisphosphonates
- 60%
- Denosumab
- 20%
Time trends in prescription
- Increase over time, but prescription rates remained highly suboptimal
- Bisphosphonate treatment dropped, denosumab treatment rose over the study period
- Sex gap persistent in Mediterranean regions, gradually reduced in Northern regions
- Treatment patterns by age groups consistent over time
- Differences by region observed
Original publication
Contemporary pharmacological management of patients after hip fracture: a population-based cohort of over 120,000 patients in Spain. Osteoporos Int. Published 12 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →